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Nephrotoxicity is a speciﬁc and serious adverse effect of cisplatin which limits its utili-
zation. Here we present an experimental approach to decipher its mechanisms focusing on
the renal distribution of Pt and Zn in cisplatin exposed mice kidneys. We combined Syn-
chrotron Radiation (S.R.) mX-ray ﬂuorescence with statistical treatments. mX-ray ﬂuores-
cence data were collected on a set of mice biopsies after cisplatin, oxaliplatin and
carboplatin injections. Even if this investigation is based on a limited number of samples,
these preliminary data seem to reveal a stronger correlation between the spatial reparti-
tion of Pt and Zn for cisplatin than for the other Pt containing drugs. The cisplatin injection
induced a redistribution of medullary Zn across the corticomedullary junction where
histological lesions develop. These results were conﬁrmed by evaluation of Pearson's and
Manders' co-localization coefﬁcients. These data suggest that Zn is involved in the neph-
rotoxicity of cisplatin. This could lead to new diagnosis, physiopathological and even
therapeutical approaches.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Each year in Europe, 3.45 million new cases of cancer
(excluding non-melanoma skin cancer) are diagnosed, andazin).
ed by Elsevier Masson SAS.1.75 million patients die. Breast (464,000 cases), colorectal
(447,000), prostate (417,000) and lung (410,000) cancers
are the most common [1]. Platinum-based anticancer
drugs, ﬁrst introduced in clinical practice as cisplatin, a
square-planar platinum (II) complex [2], are now largely
used as anti-cancer agents in many solid organ malig-
nancies including those of testis, thyroid, breast, colon andThis is an open access article under the CC BY-NC-ND license (http://
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been synthesized and evaluated for their anticancer ac-
tivity [3], only a few have entered clinical trials. Among
them, cisplatin and carboplatin are used world-wide,
oxaliplatin in a few countries, nedaplatin in Japan, hep-
taplatin in the Republic of Korea, and Lobaplatin in China
[3e6]. All these Pt molecules display the same putative
pharmacological mode of action. Pt(II) complexes are
supposed to form adducts with amine groups of proteins,
RNA and DNA. The bending of the DNA strand impedes
proper DNA transcription leading to cell death [7e9]. The
mode of action of Pt(II) molecules is still the object of
active research [9,10]. The search for new Pt anti-cancer
drugs [11,12] is driven by the need to overcome cytotox-
icity [13e15], adverse effects and limited tumor penetra-
tion of existing platinum agents [16], as well as intrinsic
and acquired resistance [17]. In addition to ototoxicity,
gastrotoxicity, myelosuppression, and allergic reactions
[18e20], the main dose-limiting adverse effect of cisplatin
is nephrotoxicity [21e23]. A number of investigations have
been performed on cells in a monolayer culture, but these
experimental conditions are far from the tumor microen-
vironment where cells are exposed to heterogeneous
conditions (large concentration gradient as the drug dif-
fuses from the blood vessels) [11].
The hallmark feature of cisplatin-induced nephrotoxi-
city is an acute tubular necrosis affecting mainly proximal
tubular cells, resulting in acute renal failure. Cisplatin-
induced nephrotoxicity is mediated by binding with thiol-
containing enzymes which can lead to oxidative stress
and subsequent cell injury [3e6]. However, although Pt
salts are chemically very close to each other, they show
various degrees of efﬁcacy and toxicity. For instance,
nephrotoxicity is a major limitation to the current use of
cisplatin but remains exceptional with oxaliplatin or car-
boplatin. Our goal is to investigate inﬂammation and
nephrotoxicity induced by these drugs using new experi-
mental approaches to provide clinicians with improved
guidelines. Convergent data reviewed [24] indicate a rela-
tionship between Zn and inﬂammation, which led us to
investigate the spatial relationship between Pt and Zn in Pt
salt exposed kidney.
In the ﬁrst step presented in this paper, we injected
mice with cisplatin, oxaliplatin and carboplatin and studied
the spatial distribution of Pt and Zn in their kidneys using
synchrotron radiation (S.R.) as the probe. More precisely,
S.R.- mX-ray Fluorescence (SR-mXRF) data [25e29] were
processed and Pearson's and Manders' co-localization co-
efﬁcients were calculated. This allowed us to obtain a
micrometer scale resolution [30e34].
2. Material and methods
Brieﬂy, 20-g C57/Black6 female mice (Charles River,
USA) were injected intraperiteonally with 13 mg/kg
equivalent Pt. Mice 1 and 2 were given 24.7 mg/kg carbo-
platin (Hospira France, France); mice 3 and 4, 20 mg/kg
cisplatin (Mylan pharmaceutics, USA); mice 5 and 6,
26.5 mg/kg oxaliplatin (Accord Healthcare Ltd, UK). Kid-
neys were sampled on day 3 at the onset of acute kidney
injury. Finally, the kidney tissues are processed intoparafﬁn. All the experiments are performed on tissue
sections.
All samples were investigated on the DiffAbs beamline
at Synchrotron SOLEIL (France). This equipment is mainly
dedicated to structural characterization by X-ray diffrac-
tion, X-ray absorption (XAS), and X-ray ﬂuorescence (XRF)
spectroscopy. The monochromator, the mirror as well as
the devices used for the detection on DiffAbs, were re-
ported in previous studies at the interface between medi-
cine and physics [35e40].
A Kirkpatrick-Baez (KB) focusing device [41] was used in
order to obtain a micron-sized X-ray beam. It consists of
two orthogonally placed curved mirrors, illuminated at a
glancing incident angle (about 0.2). If the mirrors have an
appropriate shape, the impinging X-ray beam (which can
be considered almost parallel) is focused down to micro-
meter sizes. Two bending mechanisms are placed at each
end of each mirror to monitor and change their curvature
[42,43]. As a consequence, the resulting X-ray focused spot
can be optimized in terms of intensity (photon ﬂux) and
size, depending on the experimental requirements (lateral
resolution during sampling, concentration of chemical el-
ements to be detected, etc.). The result was a clean, focused
X-ray beam with an elliptic shape and a size of about 7 
10 mm2 (full width at half maximum, vertical  horizontal,
FWHM) and a photon ﬂux of several 109 ph in the spot.
We also point out the achromatic character of the KB
focusing optics: the position and shape of the focal spot
do not change when the X-ray energy is changed for
absorption spectroscopy measurements. This makes the
KB optics the best choice for local probe spectroscopy
measurements (mXAS, mEXAFS or mXANES, but adapted as
well for mXRF).
Analysis of the ﬂuorescence spectra was performed
using the tools of the PyMca software suite [44]. Energy
calibration and a ﬁtting procedure of the ﬂuorescence lines
for each spectrum allowed us to identify and evaluate the
contribution of each element as shown in Fig. 2. Fluores-
cence maps of the four elements (Fe, Cu, Zn, Pt) correspond
to the calculated area of the main ﬂuorescence lines ﬁtted
with a Gaussian lineshape (Fe Ka, Cu Ka, Zn Ka, Pt La). In
order to single out the Pt La, a Gaussian lineshape was used
with a constant half-width at half-maximum of the peak
(HWHM, this corresponds to a region of interest) of 50 eV
allowing us to remove the Zn Kb contribution. The same
HWHM was used for the ﬁtting procedure of the ﬂuores-
cence lines of the three other elements.
This signal was used to generate maps representing Zn
and Pt spatial distribution in our samples. The cortico-
medullary junction was represented on these maps consid-
ering that the thickness of the normal female mouse cortex
and medulla is 1.26 mm and 2.4 mm, respectively [45].
The ﬂuorescence maps for the different samples and
various chemical species were analyzed using Intensity
Correlation Analysis methods [42,43] in order to highlight
possible correlations related to the presence of the various
chemical species in the tissue. Before describing the results,
let us brieﬂy describe the approach.
Consider two images (image 1 and image 2) of the same
size (same number of points), obtained for two different
species but the same sample, and let us denote by Xi,j and
Fig. 1. XRF spectrum in the 5 e 10 keV range with the different contributions
ﬁtted. Special attention has been paid to distinguish the respective contri-
butions of Zn (Kb ¼ 9572 eV) and Pt (La ¼ 9572 eV) in the region of interest,
namely between 9 and 10 KeV.
E. Esteve et al. / C. R. Chimie 19 (2016) 1580e15851582Yi,j the intensity of the pixel of coordinates (i,j) for the two
images, respectively.
The Pearson co-localization coefﬁcient is deﬁned as:
rp ¼
P
Xi;j  X

Yi;j  Y

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP 
Xi;j  X
2PYi;j  Y
2q
with the summations performed over the entire image, i.e.,
all the pixels of coordinates (i,j), and X and Y the average
intensity for the two images, respectively. The obtained
correlation of the intensity distribution in the two images is
thus independent of the brightness. With this deﬁnition, rp
takes values from 1 to þ1. A value of rp close to 1 means
that the images are strongly correlated or there is a good
co-localization of the signal in the two images (brighter
areas in image 1 correspond to brighter areas in image 2),
while rpz 0 is a signature of no correlation of the 2 images.
We also note the case of rp close to 1, in which case the
images are negatively correlated (excluded), i.e., with
reversed contrast (image 2 is the negative of image 1):
brighter areas in image 1 correspond to darker areas in
image 2 and vice versa. In the following, we will use the
Pearson co-localization coefﬁcient on the investigated ob-
ject only, i.e., the images are ﬁrst background corrected
(background is calculated outside themeasured object) and
then the above summations are performed only inside the
sample (for the pixels (i,j) for which Xi,j > 0 or Yi,j > 0). The
interpretation of the results based only on the Pearson
coefﬁcient might give rise to controversy: the results are
sensitive to noise and are reliable only for high correlation
(which is not necessarily the case for the samples depicted
in this paper).
In order to push this analysis further, other coefﬁcients
and correlation maps can be calculated. We will focus here
also on the Manders' coefﬁcients (M1 and M2): we would
like to know how well the intense pixels, above a certain
intensity threshold, in image 1 co-localizes with intensepixels in image 2 (i.e. the probability to ﬁnd bright pixels
in image 2 only at the positions of intense pixels in image
1) and vice versa. It might be, for example, that a great
part (or all) of the intense pixels of image 1 corresponds to
intense pixels in image 2 (M1 ~ 1), but the opposite is not
totally true: regions of the bright signal in the second
image might not have any correspondence to image 1
(M2 << 1). Thus, the two approaches (Pearson and Man-
ders) are not equivalent, and give complementary
information.
3. Results and discussion
Platinum-based drugs are widely employed as anti-
cancer agents because of their efﬁcacy against a variety of
tumors, but their use is limited by their nephrotoxicity.
Here, we used a combination of sophisticated physics
techniques to compare the spatial distribution and envi-
ronment of Pt in mouse kidney tissue after intraperitoneal
injection of three of these drugs selected for their varying
renal toxicity. The results show that X-ray ﬂuorescence can
detect Pt in the cortex and the medulla of kidneys of Pt-salt
exposed mice and that cisplatin is the only Pt salt that in-
duces a redistribution of Zn in the cortex.
We ﬁrst veriﬁed that using X-ray ﬂuorescence experi-
ments, we could identify trace elements including Iron,
Copper, Zinc and Platinum (Fig. 1), and isolate by mathe-
matical ﬁtting the respective contributions of Pt La and Zn
Kb (which is extrapolated from Zn Ka), (Fig. 1). After in-
jection tomice of the three Pt containing drugs, we showed
that it was possible to visualize the respective spatial dis-
tribution of Zn and Pt (Fig. 2AeC).
In mice injected with carboplatin, Pt was detected
evenly in the cortex, the medulla and at the cortico-
medullary junction (Fig. 2A and Supplementary Fig. 1). In
contrast, Zn was almost restricted to the medulla, prevail-
ing in the inner medulla. The pattern was different in mice
injected with cisplatin. In these mice, Pt was also detected
in the whole sample although it seemed to accumulate in
the medulla (Fig. 2B). Interestingly, the Zn distribution
pattern was changed and Zn was not only detected in the
medulla but also in the cortex. In mice injected with oxa-
liplatin, Pt accumulated mostly around the cortico-
medullary junction whereas Zn was only found in the
medulla (Fig. 2C).
Other investigators have assessed the role of Zn in the
nephrotoxicity of Pt anti-cancer drugs. By using laser
ablation inductively coupled plasma mass spectrometry
(LA-ICP-MS), Moreno-Gordaliza et al. [46] showed that Pt
accumulated in the kidney cortex, at the corticomedullary
junction, and in the medullar pyramids. The deep cortex
contains proximal tubule S3 segments, which are most
sensitive to cisplatin nephrotoxicity. These authors also
showed that the Zn distribution patternwas modiﬁed by Pt
exposure but in their hands, Pt and Zn seemed to be anti-
correlated. This might be due to different experimental
protocols. Because we used mice whereas they used rats,
we cannot exclude a different handling of Pt between the
two species. They studied rats at two time points (3 days for
5 mg/kg and 5 days for 16 mg/kg) while we investigated
mice 3 days after injection of 20 mg/kg. The observed
Fig. 2. (A) Carboplatin. 30 mm  60 mm Zn and Pt XRF maps collected for the sample Mouse (B) Cisplatin 30 mm  60 mm Zn and Pt XRF maps collected for the
sample Mouse 3. (C) Oxaliplatin 30 mm 60 mm Zn and Pt XRF maps collected for the sample Mouse 6. Black line denotes the sample limits and the cortico-
medullary junction. C: Cortex, M: Medulla.
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and different steps of Pt induced inﬂammation.
One strength of our study is the combination of S.R.-
mXRF at the micrometer scale with statistical treatments.
We determined Pearson's and Mander's coefﬁcients in
order to evaluate possible spatial correlation between Pt
and Zn species. The results show that such a spatial cor-
relation exists but depends on the nature of Pt drugs which
have been used, with the highest correlation being found
for cisplatin (Fig. 3). This result is in full agreement with the
detection of Zn in the cortex after cisplatin injection but not
after oxali- or carboplatin injection.
The fact that only cisplatin-induced a redistribution of
Zn to the cortex is of major interest, considering the role of
Zn in inﬂammation [47e50]. Dietary zinc is an important
immunoregulatory agent, a growth cofactor, and a cyto-
protectant with anti-oxidant, anti-apoptotic, and anti-inﬂammatory roles [49]. Moreover, zinc picolinate might
be a potential preventive agent in cisplatin-induced renal
injury through decreasing oxidative stress and inﬂamma-
tion [50].
Whether the zinc we measured is linked to a modiﬁ-
cation in zinc renal metabolism, to the activation of pro-
tective mechanisms involved in heavy metal detoxiﬁcation
with metallothionein induction, or reﬂects the recruitment
of platin induced damaged DNA linked proteins such as
ZNF143, or accumulation of proﬁbrotic metalloproteases
such as MeprinA is unclear.
The present study has limitations. It was limited to a
small number of mice which received a single dose at a
single time point. We chose a dose of cisplatin which in our
experience induces severe tubular lesions without being
lethal (the oxaliplatin and carboplatin doses were adapted
to expose all mice to the same amount of Pt) andwe chose a
Fig. 3. Correlation coefﬁcients between Zn and Pt obtained through statis-
tical analysis: Pearson (A) and Manders' coefﬁcients (B) and (C). M: Mouse.
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experimental conditions were suitable to investigate
cisplatin-induced kidney injury but they differ from the
clinical situation where the kidney biopsy is usually
delayed. The next step will be injection of subtoxic doses of
cisplatin to conﬁrm that Zn redistribution to the cortex
does correlate with kidney injury. Based on the existing
literature on trace elements in normal mouse kidneys [47],
we did not analyze a saline injected mouse control.
Although SR-mXRF is very sensitive to Pt and Zn in biolog-
ical tissue, which allows qualitative analyses of their spatialdistribution at the micrometer scale, it cannot yet be used
as a quantitative tool.
4. Conclusion and perspectives
Our study shows that SR-mXRF is a valuable tool to
assess the presence of Pt and Zn in mouse kidneys. These
preliminary data seem to reveal that cisplatin induces a
speciﬁc Zn redistribution pattern which is probably related
to its nephrotoxicity. This paves the way for other syn-
chrotron X-rays speciﬁc techniques such as EXAFS or
XANES to better describe Pt state and surrounding in bio-
logical samples. Routine renal pathology laboratories are
not equipped to assess the participation of a speciﬁc drug in
acute kidney injury and investigate the mechanisms of
toxicity; mXRF opens new perspectiveswhich hopefully will
be translated into improvement of patients' care.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at doi:10.1016/j.crci.2016.03.014.
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